Drug Profile
VTX 803
Alternative Names: VTX-803Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Vivet Therapeutics
- Developer CIMA- Universidad de Navarra; Vivet Therapeutics
- Class Gene therapies; Hepatoprotectants
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Intrahepatic cholestasis
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Intrahepatic-cholestasis in France (Parenteral)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Intrahepatic-cholestasis in Spain (Parenteral)
- 08 Mar 2023 Mirum Pharmaceuticals and Vivet Therapeutics terminates its licensing agreement for VTX 803